Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 4 studies | 20% ± 3% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 19% ± 2% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 21% ± 3% | |
endothelial cell | 4 studies | 22% ± 5% | |
epithelial cell | 4 studies | 32% ± 8% | |
CD4-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
goblet cell | 3 studies | 17% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3033.26 | 1445 / 1445 | 100% | 22.72 | 183 / 183 |
intestine | 100% | 3192.61 | 966 / 966 | 100% | 22.90 | 527 / 527 |
liver | 100% | 1836.46 | 226 / 226 | 100% | 18.45 | 406 / 406 |
ovary | 100% | 3267.08 | 180 / 180 | 100% | 30.98 | 430 / 430 |
pancreas | 100% | 1734.76 | 328 / 328 | 100% | 22.36 | 178 / 178 |
thymus | 100% | 3043.25 | 653 / 653 | 100% | 28.82 | 605 / 605 |
uterus | 100% | 3926.57 | 170 / 170 | 100% | 28.48 | 459 / 459 |
prostate | 100% | 3290.67 | 245 / 245 | 100% | 25.66 | 501 / 502 |
brain | 100% | 2427.10 | 2637 / 2642 | 100% | 24.45 | 704 / 705 |
stomach | 100% | 2181.34 | 359 / 359 | 100% | 22.26 | 285 / 286 |
skin | 100% | 3385.11 | 1809 / 1809 | 100% | 28.26 | 470 / 472 |
lung | 100% | 2592.64 | 577 / 578 | 100% | 22.11 | 1152 / 1155 |
adrenal gland | 100% | 2316.73 | 258 / 258 | 100% | 23.44 | 229 / 230 |
kidney | 100% | 2430.79 | 89 / 89 | 100% | 21.80 | 897 / 901 |
breast | 100% | 3046.62 | 459 / 459 | 99% | 24.61 | 1112 / 1118 |
bladder | 100% | 3230.05 | 21 / 21 | 99% | 25.37 | 500 / 504 |
adipose | 100% | 2689.71 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 31.76 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 24.88 | 29 / 29 |
muscle | 100% | 4292.67 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3546.10 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 27.99 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.06 | 1 / 1 |
blood vessel | 100% | 2564.20 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 1796.51 | 857 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 2329.59 | 922 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043507 | Biological process | positive regulation of JUN kinase activity |
GO_0007254 | Biological process | JNK cascade |
GO_0009408 | Biological process | response to heat |
GO_2000671 | Biological process | regulation of motor neuron apoptotic process |
GO_1904355 | Biological process | positive regulation of telomere capping |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0007165 | Biological process | signal transduction |
GO_0009411 | Biological process | response to UV |
GO_0038095 | Biological process | Fc-epsilon receptor signaling pathway |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0034612 | Biological process | response to tumor necrosis factor |
GO_0006970 | Biological process | response to osmotic stress |
GO_0051403 | Biological process | stress-activated MAPK cascade |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0051973 | Biological process | positive regulation of telomerase activity |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0006915 | Biological process | apoptotic process |
GO_0090398 | Biological process | cellular senescence |
GO_0032212 | Biological process | positive regulation of telomere maintenance via telomerase |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0009611 | Biological process | response to wounding |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0004707 | Molecular function | MAP kinase activity |
GO_0140677 | Molecular function | molecular function activator activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0019903 | Molecular function | protein phosphatase binding |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0008545 | Molecular function | JUN kinase kinase activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0004708 | Molecular function | MAP kinase kinase activity |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MAP2K7 |
Protein name | Dual specificity mitogen-activated protein kinase kinase 7 (MAP kinase kinase 7) (MAPKK 7) (EC 2.7.12.2) (JNK-activating kinase 2) (MAPK/ERK kinase 7) (MEK 7) (Stress-activated protein kinase kinase 4) (SAPK kinase 4) (SAPKK-4) (SAPKK4) (c-Jun N-terminal kinase kinase 2) (JNK kinase 2) (JNKK 2) |
Synonyms | SKK4 MKK7 MEK7 PRKMK7 JNKK2 |
Description | FUNCTION: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific role in JNK signal transduction pathway activated by pro-inflammatory cytokines. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Part of a non-canonical MAPK signaling pathway, composed of the upstream MAP3K12 kinase and downstream MAP kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated transcription of APP in response to APOE . . |
Accessions | O14733 ENST00000397979.4 [O14733-1] ENST00000397983.7 [O14733-3] ENST00000397981.7 [O14733-4] |